Wall Street flees from troubled Delcath Systems Inc. (NASDAQ:DCTH) after the cancer-treatment devices maker proceeds with a 1-to-16 reverse stock split. Delcath Systems, Inc. (NASDAQ:DCTH) stock performance was -20.30% in last session and finished the day at $3.73. Traded volume was 1.19million shares in the last session and the average volume of the stock remained 302.19K shares. The beta of the stock remained 2.55. Delcath Systems, Inc. (NASDAQ:DCTH) insider ownership is 0.10%.

Zacks restated their outperform rating on shares of Bio-Path Holdings Inc (NASDAQ:BPTH) in a report issued on Thursday, Analyst Ratings Network.com reports. They currently have a $7.00 target price on the stock. Zacks’ analyst wrote, “Bio-Path Holdings Inc (NASDAQ:BPTH) recently reported encouraging interim Phase I results of its lead drug candidate Liposomal Grb-2, which is well tolerated and has possible anti-leukemia benefits. Bio-Path Holdings Inc (NASDAQ:BPTH) rose 9.36 percent to $2.57 Wednesday on volume of 208.7K shares. The intra-day range of the stock was $2.29 to $2.59. Bio-Path Holdings Inc (NASDAQ:BPTH) has a market capitalization of $229.34million.

Summer Street started coverage on shares of Flamel Technologies S.A. (ADR) (NASDAQ:FLML). They issued a buy rating and a $25.00 target price on the stock. Flamel Technologies S.A. (ADR) (NASDAQ:FLML)’s stock on Apr 09, 2014 reported a increase of 9.80% to the closing price of $14.45. Its fifty two weeks range is $4.10 -$14.95. The total market capitalization recorded $367.25million. The overall volume in the last trading session was 427.1K shares. In its share capital, FLML has 25.47million outstanding shares.

Back on December 13th, Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced a simultaneous reverse split, capital raise at $5.95 along with an uplisting to Nasdaq. CRT Capital was the sole book-running manager for the offering and according to Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s Director of Investor Relations & Corporate Communications, Mark Flather, there were 27 institutions that participated. On Wednesday, shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) advanced 6.00% to close the day at $5.83. Company monthly performance is recorded as -7.17%. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) quarterly revenue growth is -6.42%.